1-[4-Acetyl-1-(2,4-dimethoxy-phenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-ethanone | 461437-65-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 1-[4-Acetyl-1-(2,4-dimethoxy-phenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-ethanone
• 英文别名: 1-[4-acetyl-1-(2,4-dimethoxyphenyl)-2,5-dimethylpyrrol-3-yl]ethanone
• CAS: 461437-65-0
• 化学式: C₁₈H₂₁NO₄
• mdl: MFCD03250083
• 分子量: 315.369
• InChiKey: SSJAJVNOGKMGCK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  57.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-[4-Acetyl-1-(2,4-dimethoxy-phenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-ethanone 在 三溴化硼 、 potassium carbonate 、 肼 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 6-(2,4-Diethoxyphenyl)-1,4,5,7-tetramethyl-6H-pyrrolo[3,4-d]pyridazine
  参考文献：
  名称：

  Synthesis and biological evaluation of 6-aryl-6 H -pyrrolo[3,4- d ]pyridazine derivatives as high-affinity ligands of the α 2 δ subunit of voltage-gated calcium channels

  摘要：

  A novel class of 2H-pyrrolo[3,4-c]pyridazine ligands of the alpha(2)delta subunit of voltage-gated calcium channels is described. Compound 4a with high affinity toward alpha(2)delta was identified through structure-activity relationship studies of the lead compound. Tritiated ligand [H-3]-4b was synthesized to demonstrate that this ligand binds to the same site as Gabapentin toward alpha(2)delta subunit of voltage-gated calcium channels. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.02.070
• 作为产物：
  描述：

  3,4-二乙酰基-2,5-己二酮 、 2,4-二甲氧基苯胺 以to give 1-[4-acetyl-1-(2,4-dimethoxy-phenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-ethanone as yellow solid的产率得到1-[4-Acetyl-1-(2,4-dimethoxy-phenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-ethanone
  参考文献：
  名称：

  Treatment of neuropathic pain with 6h-pyrrolo[3,4-d]pyridazine compounds

  摘要：

  6H-吡咯并[3,4-d]吡嗪化合物及其作为电压门控钙通道（VGCC）配体的使用方法，可用于治疗神经病性疼痛、精神和情绪障碍，例如精神分裂症、焦虑、抑郁、惊恐和双相情感障碍，以及治疗疼痛、帕金森病、认知功能障碍、癫痫、昼夜节律紊乱、药物成瘾、药物滥用、戒断症状等。

  公开号：

  US20060154929A1

文献信息

• Treatment of neuropathic pain with 6h-pyrrolo[3,4-d]pyridazine compounds
  申请人：Anker Burke Naomi

  公开号：US20060154929A1

  公开（公告）日：2006-07-13

  6H-pyrrolo[3,4-d]pyridazine compounds and methods of their use of as ligands of voltage gated calcium channels (VGCC), useful in the treatment of neuropathic pain, and psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, panic, and bipolar disorder, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm disorders, drug addiction, drug abuse, drug withdrawal and other.

  6H-吡咯并[3,4-d]吡嗪化合物及其作为电压门控钙通道（VGCC）配体的使用方法，可用于治疗神经病性疼痛、精神和情绪障碍，例如精神分裂症、焦虑、抑郁、惊恐和双相情感障碍，以及治疗疼痛、帕金森病、认知功能障碍、癫痫、昼夜节律紊乱、药物成瘾、药物滥用、戒断症状等。
• Treatment of neuropathic pain with 6H-pyrrolo[3,4-d]pyridazine compounds
  申请人：Merck & Co. Inc.

  公开号：US07465730B2

  公开（公告）日：2008-12-16

  6H-pyrrolo[3,4-d]pyridazine compounds and methods of their use of as ligands of voltage gated calcium channels (VGCC), useful in the treatment of neuropathic pain, and psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, panic, and bipolar disorder, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm disorders, drug addiction, drug abuse, drug withdrawal and other.

  6H-吡咯并[3,4-d]吡嗪化合物及其作为电压门控钙通道（VGCC）配体的应用方法，可用于治疗神经病理性疼痛和精神和情绪障碍，例如精神分裂症、焦虑、抑郁、恐慌和躁症，以及治疗疼痛、帕金森氏病、认知功能障碍、癫痫、昼夜节律紊乱、药物成瘾、药物滥用、药物戒断等。
• TREATMENT OF NEUROPATHIC PAIN WITH 6H-PYRROLO(3,4-D)PYRIDAZINE COMPOUNDS
  申请人：Merck & Co., Inc.

  公开号：EP1539168A2

  公开（公告）日：2005-06-15
• US7465730B2
  申请人：——

  公开号：US7465730B2

  公开（公告）日：2008-12-16
• [EN] TREATMENT OF NEUROPATHIC PAIN WITH 6H-PYRROLO[3,4-D]PYRIDAZINE COMPOUNDS<br/>[FR] TRAITEMENT DE LA DOULEUR NEUROPATHIQUE AU MOYEN DE COMPOSES 6H-PYRROLO[3,4-D]PYRIDAZINE
  申请人：MERCK & CO INC

  公开号：WO2004006836A2

  公开（公告）日：2004-01-22

  6H-pyrrolo[3,4-d]pyridazine compounds and methods of their use of as ligands of voltage gated calcium channels (VGCC), useful in the treatment of neuropathic pain, and psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, panic, and bipolar disorder, as well as in the treatment of pain, Parkinson s disease, cognitive dysfunction, epilepsy, circadian rhythm disorders, drug addiction, drug abuse, drug withdrawal and other